Epigenetic and Metabolic Regulation of Aging and Aging-Related Diseases

Transcription

1 Join Us for the Keystone Symposia conference on: Epigenetic and Metabolic Regulation of Aging and Aging-Related Diseases May 1 5, 2016 Hilton Santa Fe Historic Plaza Hotel Santa Fe, New Mexico Scientific Organizers: Anne Brunet, David M. Sabatini and Shelley L. Berger Aging is one of the greatest fundamental mysteries in biology, and arguably its next frontier. Long thought to be inexorable, aging has in fact been shown to be malleable due to specific changes in genes or environment. This meeting will cover the most exciting questions at the forefront of the field: How can external stimuli delay aging in a long-lasting, yet reversible, manner? Does the integration of external stimuli to modulate aging differ among cells with vastly diverse functions somatic maintenance, tissue regeneration and the immortal germline? Is aging a synchronous process, and how do the different cells and systems communicate? How do diseases of aging develop, and what can be done to prevent or reverse them? To address these questions, the symposium gathers investigators from completely different areas to bring an interdisciplinary approach to aging. The meeting will focus on the emerging nexus between two key aging regulators epigenetic states of the genome and metabolic status and will highlight innovative technologies and the newest discoveries in aging and diseases. It will address questions from different perspectives, taking advantage of model organisms with drastically divergent lifespans and aging strategies. Session Topics: Epigenetic Regulation of Aging Workshop 1: New Animal Models Transcriptional and Noncoding RNA Networks in Aging Autophagy, Inflammaging and Metabolism The Immortal Germline: Reprogramming and Transgenerational Inheritance Epigenetic and Metabolic Regulation of Aging Stem Cells Systemic Regulation of Aging Epigenetics of Age-Related Diseases Workshop 2: Therapeutic Approaches Human Aging and Therapeutics CONFIRMED SPEAKERS (as of January 29, 2016): Peter D. Adams Adam Antebi Steven E. Artandi Shelley L. Berger Anne Brunet Andrew G. Dillin Vishva M. Dixit Margaret A. Goodell Marcia C. Haigis Malene Hansen Trey Ideker Leanne Jones Cynthia Kenyon Tony Kouzarides Sean J. Morrison Coleen T. Murphy Linda Partridge* J. Andrew Pospisilik Thomas A. Rando David M. Sabatini Amita Sehgal Ramin Shiekhattar Ali Shilatifard David A. Sinclair P. Eline Slagboom Li-Huei Tsai Amy J. Wagers Tony Wyss-Coray *Keynote Speaker Submitting an abstract is a great way of participating in the conference through poster presentation and possible selection for a short talk. Abstract Deadline: Feb 2, 2016 Discounted Registration Deadline: Mar 1, 2016 For additional details, visit a 501(c)(3) nonprofit educational organization

2 SUNDAY, APRIL 26 Arrival and Registration MONDAY, APRIL 27 Keynote Address *Guido Silvestri, Emory University School of Medicine, *Steven G. Deeks, University of California, San Francisco, Françoise Barré-Sinoussi, Institut Pasteur, France HIV Cure as an Aspirational Goal Biology of HIV Latency Monsef Benkirane, Institut de Genetique Humaine, France Toward Development of an Animal Model Dedicated to Explore HIV-1 Persistence *Carine Michele Van Lint, University of Brussels, Belgium Molecular Mechanisms of HIV-1 Postintegration Latency: Implications for Therapeutic Strategies Lillian B. Cohn, Rockefeller University, Short Talk: HIV-1 Integration Landscape in Active and Latent Infection Kai Deng, Sun Yat-sen University, China Short Talk: The Establishment of HIV-1 Latency Is Restricted within a Small Subset of Primary CD4+ T Cells and Can Be Prevented by Viral-Specific CTLs Valentina Vongrad, University Hospital Zürich, Switzerland Short Talk: Longitudinal Patterns of HIV-1 Integration Sites (IS) in CD4+ T Cell Subsets in vivo Ronald N. Germain, NIAID, National Institutes of Health, Imaging Immunity: Creating a Spatiotemporal Understanding of Host Defense *Robert F. Siliciano, Johns Hopkins University School of Medicine, HIV Reservoirs: What We Know and What We Don't Know Una O'Doherty, University of Pennsylvania Medical Center, HIV Reservoir Expression Douglas D. Richman, University of California, San Diego, Measuring the Latent Reservoir TUESDAY, APRIL 28 CD4 T Cells as Reservoir Chen Dong, Tsinghua University, China T Cell Subsets in Immunity *Sharon R. Lewin, University of Melbourne, Australia Chemokines and the HIV Reservoir in CD4 T Cells Richard A. Koup, NIAID, National Institutes of Health, Tfh Cells Are a Site of Active HIV Replication Matthieu Perreau, University Hospital of Lausanne, Switzerland Short Talk: Lymph node PD-1+/Tfh Memory CD4 T Cells Are the Major Source of HIV-1 Replication Competent and Infectious Virus in Long-Term Treated Aviremic HIV-Infected Subjects Joseph K. Wong, University of California, San Francisco, Charateristics of Tissue HIV Reservoirs in vivo Eli Andrew Boritz, NIAID, National Institutes of Health, Short Talk: Mechanisms of HIV Persistence in HIV Controllers Poster Session 1 Workshop 2: Modulations of the Immune System to Reduce the Size of HIV Reservoirs Workshop 1: HIV Reservoirs, Clinical Care and Clinical Results *Asier Sáez-Cirión, Institut Pasteur, France *Christine Rouzioux, Necker Hospital and University of Paris Descartes, France Zelda Euler, Ragon Institute of MGH, MIT and Harvard, HIV Reservoirs Measurement in Clinical Care: Where Are We Going? Eradication of HIV Reservoirs with Antibody-Mediated Killing Katherine M. Bruner, Johns Hopkins University School of Medicine, Edward A. Berger, NIAID, National Institutes of Health, Targeted Cell Killing to Achieve a (Functional) Cure: Different Analysis of HIV-1 Genomes in the Latent Reservoir Indicates Rapid Strategies for Acute Versus Chronic Infection Accumulation of Defective Proviruses Selena Viganò, Ragon Institute, Rémi Fromentin,, Canada Immune Correlates of HIV-1 DNA Decrease during Treatment with Distribution of Cellular HIV Reservoirs after more than 15 Years of ART Pegylated IFN-alpha in HIV/HCV Co-Infected Patients Alexander O. Pasternak, Academic Medical Center of the University Emily R. Roberts, University of Pennsylvania, of Amsterdam, Netherlands Rapid Evolution of SIV-Specific CD8 T Cell Cytolytic Potential during Long-Term Effect of Temporary ART during Primary HIV Infection on Acute SIV Infection the Viral Reservoir Kellie N. Smith, Johns Hopkins University School of Medicine, Miles P. Davenport, University of New South Wales, Australia Effective Targeting of the HIV Reservoir Requires a Broad de novo Low Frequency of HIV Rebound after Antiretroviral Treatment Induction of Primary Rather than Memory CTL Interruption Guido Silvestri, Emory University School of Medicine, Anti-Apoptosis Agent Preserves CD4 T Cells and Prevents Disease Detection and Quantification of HIV Reservoirs Progression in SIV-Infected Rhesus macaques George B. Kyei, Washington University, Largazoles Are a Novel Group of Lysine Deacetylase Inhibitors that Potently Reactivate HIV from Latency Petronela Ancuta, Centre de Recherche de l'universite de Montreal, Canada Persistence of Replication Competent HIV-1 Reservoirs under ART in Central Memory Th17 Cells

3

4 Non-CD4 T Cell Reservoirs Jason M. Brenchley, NIAID, National Institutes of Health, Phagocytosis of SIV-Infected T Cells Can Explain Viral DNA within Myeloid Cells in vivo Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection Melissa J. Churchill, Burnet Institute for Medical Research, Australia Microglia and the CNS as a Sanctuary for HIV Serge Benichou, Cochin Institute, France Short Talk: Productive HIV-1 Infection of Macrophages by Viral Cell-to-Cell Transfer from Infected CD4+ T Lymphocytes Poster Session 2 WEDNESDAY, APRIL 29 Functional Eradication of HIV Reservoirs: Current Approaches and New Directions *Steven G. Deeks, University of California, San Francisco, Short-Term Disulfiram to Reverse Latent HIV Infection Thomas A. Rasmussen, Aarhus University Hospital, Denmark Reversal of HIV-1 Latency by HDAC Inhibitors: Part of a Curative Strategy? Paula M. Cannon, University of Southern California, Keck School of Medicine, Targeted Nuclease Approaches for a Functional Cure Romas Geleziunas, Gilead Sciences, Inc., Concepts of Combination Therapy to Achieve ART-Free HIV Remission R. Brad Jones, Ragon Institute of MGH, MIT and Harvard, Short Talk: Cytotoxic T-Lymphocytes in Combination with the IL-15 Superagonist ALT-803 Eliminate Latently HIV-Infected Autologous CD4+ T-Cells from Natural Reservoirs Joumana Zeidan, Case Western Reserve University, Short Talk: Decay of the HIV Reservoir Post Autologous Transfer of ZFN CCR5 Modified CD4 T Cells (SB-728-T) Correlates with Generation of a T Memory Stem Cell-Like Population and Enhanced HIV-Specific CD8 T Cell Polyfunctionality NeuroHIV Workshop Program:HIV Persistence in the CNS: Controversies and Challenges NeuroHIV Workshop Program: Investigating HIV Persistence in the CNS *Victor Valcour, University of California, San Francisco, Jeymohan Joseph, NIMH, National Institutes of Health, Opening Remarks Janice E. Clements, Johns Hopkins University, HIV CURE: Reactivation of SIV in Plasma, CSF and CNS in the SIV Macaque Model Sandhya Vasan, US Military HIV Research Program, CNS Findings in a Non-Accelerated SHIV Macaque Model Sarah E. Palmer, University of Sydney, Australia Low Level CSF HIV Persistence during Systemic Antiretroviral Suppression Richard W. Price, University of California, San Francisco, Persistent CNS Immune Activation in Treated HIV Serena Spudich, Yale University, Early Detection of HIV in the CNS and Impact of Early Treatment NeuroHIV Workshop Program: State of the Science Discussion Panels A and B Panel A: Are Myeloid Cells Infected by HIV? *Steven G. Deeks, University of California, San Francisco, Lishomwa C. Ndhlovu, University of Hawaii, Jason M. Brenchley, NIAID, National Institutes of Health, Mario Stevenson, University of Miami, Leonard M. Miller School of Medicine, J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, Karl Salzwedel, NIAID, National Institutes of Health, Panel B: Is the CNS a Potential Reservoir for HIV? *Jintanat Ananworanich, US Military HIV Research Program, Melissa J. Churchill, Burnet Institute for Medical Research, Australia Douglas D. Richman, University of California, San Diego, Ronald I. Swanstrom, University of North Carolina at Chapel Hill, David M. Margolis, University of North Carolina at Chapel Hill, How to Fight Immune Exhaustion? Daniel E. Kaufmann, University of Montreal, Canada Co-Inhibitory Pathways and HIV Persistence Stephen Mason, Bristol-Myers Squibb, Approaches to HIV Remission *Rafick-Pierre Sekaly, Case Western Reserve University, Promoting CD4 Differentiation Colleen S. McGary, Emory University, Short Talk: CTLA-4-Expressing CD4 T Cells Are Critical Contributors to SIV Viral Persistence Poster Session 3 THURSDAY, APRIL 30 Strengths and Weaknesses of NHP Models *Guido Silvestri, Emory University School of Medicine, Optimizing the NHP Model for Cure Studies Caroline P.B. Passaes, Institut Pasteur, France Animal Models of Spontaneous Control: Lessons Learned and Future Directions Gregory Q. Del Prete, Frederick National Laboratory for Cancer Research, Development and Utilization of Non-Human Primate Models of Combination Antiretroviral Therapy for Studies of HIV Functional Cure/Eradication Afam Okoye, Oregon Health & Science University, Early Antiretroviral Therapy Limits Viral Reservoir in SIV-Infected Macaques

5 Pamela J. Skinner, University of Minnesota, Short Talk: Location, Abundance and Phenotype of Follicular SIV-Specific CTL during Chronic Infection Emily Ryan, Emory University, Short Talk: Loss of Function of Intestinal Th17 and Th22 Cells Contributes to Persistent Immune Activation in SIV-Infected Rhesus macaques Khader Ghneim, Case Western Reserve University, Short Talk: FOXO3 and the Interferon Pathway Regulate Immune Reconstitution and the Size of the HIV Reservoir Workshop 4: Strategies to Reduce HIV Reservoirs: The Point of View of the Patient Perspectives on the Acceptability of HIV Cure Trials: The Challenges for Physicians and PLWHIV (ANRS APSEC) Sara Morón-López, AIDS Research Institute - IrsiCaixa, Spain Impact of IFNalpha-2a on the Replication-Competent HIV-1 Reservoir in CD4+ T Cells Genevieve Clutton, University of North Carolina, Differential Effects of HIV Latency Reversing Agents on T Cell Phenotype and Function: Implications for HIV Cure Miguel de Mulder Rougvie, George Washington University, Modulation of HERV Family Expression after Treatment with HDAC Inhibitors Sulggi Angela Lee, University of California, San Francisco, Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Johanna Tauriainen, Karolinska Institutet, Sweden Sustained Expression of the Inhibitory Receptor TIGIT Is Linked to CD8 T Cell Exhaustion Despite Successful ART Limitations of Antiretroviral Therapy and New Perspectives *Courtney Fletcher, University of Nebraska Medical Center, Is There a Pharmacologic Basis for Persistent HIV Replication? Asier Sáez-Cirión, Institut Pasteur, France Treat Early Is the Clue? Example of the Post-Treatment Controllers Jintanat Ananworanich, US Military HIV Research Program, Effects of Treatment during Acute HIV Infection on HIV Persistence Meeting Wrap-Up: Outcomes and Future Directions (Organizers) FRIDAY, MAY 1 Departure